- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Locally advanced or metastatic non-small cell lung cancer (NSCLC) Stage IV (metastatic) NSCLC Extensive-stage small cell lung cancer Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma Resected early stage (Stage II to IIIA) NSCLC
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 755KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 156KB)
Atezolizumab – March 2024
Atezolizumab: Solution for subcutaneous injection containing atezolizumab 1875 mg in 15 mL; Tecentriq® SC
Last updated
30 May 2025